Liz Barrett, UroGen CEO, at the 2019 Forbes Healthcare Summit (Steven Ferdman/Getty Images)
August 27, 2020 09:27 AM EDTUpdated 10:09 AM
R&D

That pipeline Ab­b­Vie ac­quired in the $63B Al­ler­gan buy­out? It’s not do­ing so well

John Carroll

Editor & Founder

An­oth­er Al­ler­gan project picked up by Ab­b­Vie in their $63 bil­lion buy­out has turned sour.

Uro­Gen $URGN re­port­ed Thurs­day morn­ing that a Phase II …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

SK, Car­lyle bol­ster blue­bird bio bid; Theri­ni Bio rais­es $39M

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

PBM over­haul and drug price ne­go­ti­a­tions make the cut in Re­pub­li­can­s' tax bill

A service from the Financial Times